[{"orgOrder":0,"company":"Convalife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CVL237","moa":"Alpha-synuclein","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Convalife","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Convalife \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Convalife \/ Inapplicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":6.5,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":6.5,"dosageForm":"Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"Momenta Pharmaceuticals","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Nipocalimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Momenta Pharmaceuticals","amount2":6.5,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":6.5,"dosageForm":"Infusion","sponsorNew":"Momenta Pharmaceuticals \/ Johnson & Johnson","highestDevelopmentStatusID":"9","companyTruncated":"Momenta Pharmaceuticals \/ Johnson & Johnson"},{"orgOrder":0,"company":"Beijing Mabworks Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MIL62","moa":"CD20","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Beijing Mabworks Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beijing Mabworks Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beijing Mabworks Biotech \/ Inapplicable"},{"orgOrder":0,"company":"GSK","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Belimumab","moa":"Tumor necrosis factor ligand superfamily member 13B","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"GSK \/ Inapplicable"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linsitinib","moa":"Insulin receptor | Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sling Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Linsitinib","moa":"Insulin receptor | Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sling Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Linsitinib","moa":"Insulin receptor | Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sling Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sling Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Linsitinib","moa":"Insulin receptor | Insulin-like growth factor I receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sling Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sling Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sling Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivarmacitinib","moa":"Janus kinase 1 (JAK-1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etrasimod Arginine","moa":"Sphingosine 1-phosphate receptor Edg-8 | Sphingosine 1-phosphate receptor Edg-6 | Sphingosine 1-phosphate receptor Edg-1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Mohammed Bin Rashid University of Medicine and Health Sciences","sponsor":"Mediclinic Middle East | Rashid Hospital | Dubai Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Frondanol","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Mohammed Bin Rashid University of Medicine and Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mohammed Bin Rashid University of Medicine and Health Sciences \/ Mediclinic Middle East | Rashid Hospital | Dubai Health Authority","highestDevelopmentStatusID":"9","companyTruncated":"Mohammed Bin Rashid University of Medicine and Health Sciences \/ Mediclinic Middle East | Rashid Hospital | Dubai Health Authority"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ABC008","moa":"Killer cell lectin-like receptor subfamily G member 1 (KLRG1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Syneos Health","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Syneos Health"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Institute for Developing Science and Health Initiatives, Bangladesh","sponsor":"Universal Medical College Hospital | Green Life Center for Rheumatic Care & Research, Bangladesh | Incepta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Institute for Developing Science and Health Initiatives, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Institute for Developing Science and Health Initiatives, Bangladesh \/ Universal Medical College Hospital | Green Life Center for Rheumatic Care & Research, Bangladesh | Incepta Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Institute for Developing Science and Health Initiatives, Bangladesh \/ Universal Medical College Hospital | Green Life Center for Rheumatic Care & Research, Bangladesh | Incepta Pharmaceuticals"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Redmile Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series B Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.16,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Redmile Group","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Redmile Group"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Series C Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ RA Capital Management","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ RA Capital Management"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BlackRock Fund","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ BlackRock Fund","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ BlackRock Fund"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Batoclimab","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nona Biosciences \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nona Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"B007","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Jiaolian Drug Research and Development Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Shanghai Jiaolian Drug Research and Development Co., Ltd","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"B007","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Jiaolian Drug Research and Development Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Jiaolian Drug Research and Development Co., Ltd \/ Shanghai Pharmaceuticals Holding Co.,Ltd"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Series C Financing","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.29999999999999999,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Access Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Access Biotechnology"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Affibody","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Affibody","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Affibody"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Acelyrin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Izokibep","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Acelyrin","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acelyrin \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Acelyrin \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ABC008","moa":"Killer cell lectin-like receptor subfamily G member 1 (KLRG1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Abcuro, Inc","sponsor":"Mass General Brigham Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Series A Financing","leadProduct":"Ulviprubart","moa":"KLRG1","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Abcuro, Inc","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Abcuro, Inc \/ Mass General Brigham Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Abcuro, Inc \/ Mass General Brigham Ventures"},{"orgOrder":0,"company":"University of Tokyo","sponsor":"Japan Agency for Medical Research and Development | Zenyaku Kogyo","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University of Tokyo","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Tokyo \/ Japan Agency for Medical Research and Development | Zenyaku Kogyo","highestDevelopmentStatusID":"9","companyTruncated":"University of Tokyo \/ Japan Agency for Medical Research and Development | Zenyaku Kogyo"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"HBM9161","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SHR-1314","moa":"Interleukin 17A","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Suzhou Suncadia Biopharmaceuticals Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Children's Hospital Medical Center, Cincinnati","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Avsola","moa":"TNF-alpha","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Children's Hospital Medical Center, Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Medical Center, Cincinnati \/ National Institute of Diabetes and Digestive and Kidney Diseases | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"9","companyTruncated":"Children's Hospital Medical Center, Cincinnati \/ National Institute of Diabetes and Digestive and Kidney Diseases | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Shanghai Mabgeek Biotech.Co.Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"MG-K10","moa":"IL-4R?","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Shanghai Mabgeek Biotech.Co.Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Mabgeek Biotech.Co.Ltd \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Mabgeek Biotech.Co.Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Glia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Pro-Ocular","moa":"Progesterone receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Glia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Glia \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Glia \/ Inapplicable"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2021","type":"Merger","leadProduct":"CYTO-200","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Cleveland Clinic","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland Clinic"},{"orgOrder":0,"company":"Universitaire Ziekenhuizen KU Leuven","sponsor":"VIB","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Universitaire Ziekenhuizen KU Leuven","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitaire Ziekenhuizen KU Leuven \/ VIB","highestDevelopmentStatusID":"9","companyTruncated":"Universitaire Ziekenhuizen KU Leuven \/ VIB"},{"orgOrder":0,"company":"University Hospital Schleswig-Holstein","sponsor":"Ced Service | Gesellschaft f\u00fcr Therapieforschung mbH | German Federal Ministry of Education and Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nicotinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University Hospital Schleswig-Holstein","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Schleswig-Holstein \/ Ced Service | Gesellschaft f\u00fcr Therapieforschung mbH | German Federal Ministry of Education and Research","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital Schleswig-Holstein \/ Ced Service | Gesellschaft f\u00fcr Therapieforschung mbH | German Federal Ministry of Education and Research"},{"orgOrder":0,"company":"Cytocom","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"CYTO-201","moa":"Mu opioid receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Cytocom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytocom \/ Cleveland Clinic","highestDevelopmentStatusID":"9","companyTruncated":"Cytocom \/ Cleveland Clinic"},{"orgOrder":0,"company":"MRM Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Inapplicable"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PQGrass309","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Allergy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Allergy Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Allergy Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Hadassah Medical Organization | Medis | Pharma Medica Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Inapplicable"},{"orgOrder":0,"company":"MRM Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"MH002","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRM Health \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"MRM Health \/ Inapplicable"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Laidlaw & Company","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Laidlaw & Company"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
